CN103997894B - 乳癌的治疗 - Google Patents

乳癌的治疗 Download PDF

Info

Publication number
CN103997894B
CN103997894B CN201280048192.2A CN201280048192A CN103997894B CN 103997894 B CN103997894 B CN 103997894B CN 201280048192 A CN201280048192 A CN 201280048192A CN 103997894 B CN103997894 B CN 103997894B
Authority
CN
China
Prior art keywords
substituted
alkyl
compound
formula
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280048192.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103997894A (zh
Inventor
A·A·普罗特
J·瑞彻
D·克齐兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maddie Wilson Prostate Treatment Co Ltd
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Medivation Prostate Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103997894(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Colorado Boulder, Medivation Prostate Therapeutics LLC filed Critical University of Colorado Boulder
Publication of CN103997894A publication Critical patent/CN103997894A/zh
Application granted granted Critical
Publication of CN103997894B publication Critical patent/CN103997894B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280048192.2A 2011-07-29 2012-07-27 乳癌的治疗 Active CN103997894B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
US61/513,361 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
CN103997894A CN103997894A (zh) 2014-08-20
CN103997894B true CN103997894B (zh) 2016-08-24

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280048192.2A Active CN103997894B (zh) 2011-07-29 2012-07-27 乳癌的治疗

Country Status (18)

Country Link
US (4) US9517229B2 (enExample)
EP (4) EP2739153B1 (enExample)
JP (2) JP6158180B2 (enExample)
KR (1) KR101923250B1 (enExample)
CN (1) CN103997894B (enExample)
BR (1) BR112014002200A2 (enExample)
CA (1) CA2843417C (enExample)
CY (1) CY1121038T1 (enExample)
DK (1) DK2739153T3 (enExample)
EA (1) EA028452B1 (enExample)
ES (1) ES2696074T3 (enExample)
HU (1) HUE040524T2 (enExample)
MX (1) MX359664B (enExample)
PH (1) PH12014500248B1 (enExample)
PL (1) PL2739153T3 (enExample)
PT (1) PT2739153T (enExample)
SI (1) SI2739153T1 (enExample)
WO (1) WO2013066440A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
DK2945628T3 (da) * 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP3065549A4 (en) * 2013-11-07 2017-05-24 Deciphera Pharmaceuticals, LLC Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
EP3148336B1 (en) * 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
RU2017120330A (ru) * 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019387367A1 (en) * 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
JP2023536636A (ja) * 2020-08-03 2023-08-28 オンコサイト・コーポレイション 腫瘍の分類及び応答性の予測
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454002A (zh) * 2006-03-27 2009-06-10 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
WO2010099238A1 (en) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2608436C (en) 2005-05-13 2015-03-24 The Regents Of The University Of California Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
EP2220050A2 (en) * 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
US8710086B2 (en) 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
US10175240B2 (en) 2012-08-23 2019-01-08 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
RU2017120330A (ru) 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454002A (zh) * 2006-03-27 2009-06-10 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
WO2010099238A1 (en) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds

Also Published As

Publication number Publication date
CY1121038T1 (el) 2019-12-11
US20190262315A1 (en) 2019-08-29
EP3610731A1 (en) 2020-02-19
PH12014500248A1 (en) 2014-03-17
WO2013066440A9 (en) 2013-07-18
JP2014524934A (ja) 2014-09-25
PH12014500248B1 (en) 2018-08-31
DK2739153T3 (en) 2018-12-03
CN103997894A (zh) 2014-08-20
EP2739153A4 (en) 2015-03-11
CA2843417C (en) 2018-08-21
US20140296312A1 (en) 2014-10-02
US10111861B2 (en) 2018-10-30
US9517229B2 (en) 2016-12-13
HK1198867A1 (en) 2015-06-19
JP2017141269A (ja) 2017-08-17
ES2696074T3 (es) 2019-01-14
HUE040524T2 (hu) 2019-03-28
US20210069154A1 (en) 2021-03-11
PT2739153T (pt) 2018-11-28
MX2014001218A (es) 2014-08-22
HK1201413A1 (en) 2015-09-04
SI2739153T1 (sl) 2018-12-31
BR112014002200A2 (pt) 2017-03-07
EP3430907A1 (en) 2019-01-23
KR101923250B1 (ko) 2018-11-28
EA028452B1 (ru) 2017-11-30
EP3791724A1 (en) 2021-03-17
PL2739153T3 (pl) 2019-04-30
JP6158180B2 (ja) 2017-07-05
KR20140107174A (ko) 2014-09-04
EA201400178A1 (ru) 2014-11-28
EP2739153A1 (en) 2014-06-11
EP2739153B1 (en) 2018-08-22
MX359664B (es) 2018-10-05
US20170087132A1 (en) 2017-03-30
WO2013066440A1 (en) 2013-05-10
CA2843417A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
JP6158180B2 (ja) 乳がんの処置
WO2022133731A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
CN101370497B (zh) 包含parp抑制剂和细胞毒性剂的联合产品及用途
JP2020193234A (ja) 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤
JP6433085B2 (ja) がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
US9464093B2 (en) Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer
WO2013067142A1 (en) Compounds and treatment methods
WO2013067151A1 (en) Treatment methods using diarylthiohydantoin derivatives
CN105579439B (zh) 辐射减轻性药物制剂
JP2010514734A (ja) 腸障害の治療のためのイソソルビドモノニトレート誘導体
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
JP2022527451A (ja) Ｐｋｍ２モジュレーターおよびその使用方法
HK1201413B (en) Treatment of breast cancer
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
WO2025237421A1 (zh) 作为雄激素受体调节剂的新型偶联分子及其应用
HK1198867B (en) Treatment of breast cancer
HK1229744B (zh) 2-乙酰基萘并[2，3-b]呋喃-4，9-二酮用於治疗癌症的用途
JP2016525118A (ja) がんの治療のためのｐｉｍキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201413

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: American California

Co-patentee after: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee after: Mehdi Vee Xun prostate therapeutics limited liability company

Address before: American California

Co-patentee before: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee before: Mai Diweixun prostate treatment limited company

CP01 Change in the name or title of a patent holder
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1201413

Country of ref document: HK

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: American Colorado

Co-patentee after: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee after: Maddie Wilson prostate treatment Co., Ltd.

Address before: American California

Co-patentee before: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee before: Mehdi Vee Xun prostate therapeutics limited liability company

CP02 Change in the address of a patent holder

Address after: New York State, USA

Patentee after: Maddie Wilson prostate treatment Co.,Ltd.

Patentee after: THE REGENTS OF THE University OF COLORADO

Address before: Colorado, USA

Patentee before: Maddie Wilson prostate treatment Co.,Ltd.

Patentee before: THE REGENTS OF THE University OF COLORADO

CP02 Change in the address of a patent holder